According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, ...

Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...

Introduction Therapeutic antibodies are laboratory-engineered proteins designed to replicate the immune system's natural ability to combat dise ...

A single dose of the COVID-19 monoclonal antibody therapy developing Regeneron reduced the risk of contracting the virus by around 82% for up to eight months, according to new trial data.

and anti-CD38 monoclonal antibody, and Regeneron is planning to file linvoseltamab in the same setting. Dosing could be another point of difference for the new drug. Elrexfio has a slight edge ...

Learn more about whether Ultragenyx Pharmaceutical Inc. or Vericel Corporation is a better investment based on AAII's A+ ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Four monoclonal antibodies (mAbs) gained approval in 2009 ... is also marketed by Regeneron Pharmaceuticals, of Tarrytown, New York. Ilaris is, however, the first antibody to be successfully ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...